Gilead (GILD) CEO says Epclusa list price will be $74,760 for 12 weeks - Bloomberg
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Gilead (Nasdaq: GILD) CEO John Milligan says Epclusa list price will be $74,760 for 12 weeks, according to Bloomberg.
UPDATE - News follows the FDA Approval of Epclusa in all hepatits C genotypes, which was announced on Tuesday morning.
Notably, Epclusa's list price is lower than $84,000 for Sovaldi and $94,500 for a Harvoni treatment.
Mulligan note that Epclusa's holds the
best price for the system and the company.
Shares of Gilead are up 4 percent Tuesday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Walt Disney (DIS) Quickly Falls to Low, Down 4% Following CEO Comments
- AbCellera (ABCL) Notes Partner Eli Lilly & Co. (LLY) Announces Joint Procurement Agreement in Europe for Bamlanivimab and Etesevimab to Treat COVID-19
- Coinbase (COIN) To Propose Crypto Regulations To U.S. Officials - CoinDesk
Create E-mail Alert Related CategoriesFDA, Management Comments, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!